Clinicopathologic Implications of EpCAM and Sox2 Expression in Breast Cancer

[1]  V. Zagonel,et al.  Targeted approaches to triple-negative breast cancer: current practice and future directions. , 2013, Current medicinal chemistry.

[2]  Shu-dong Yang,et al.  Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer , 2013, Medical Oncology.

[3]  A. Adamczyk,et al.  Relationships Between Immunophenotype, Ki-67 Index, Microvascular Density, Ep-CAM/P-cadherin, and MMP-2 Expression in Early-stage Invasive Ductal Breast Cancer , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  G. Untergasser,et al.  Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines , 2012, BMC Cancer.

[5]  Han‐Chung Wu,et al.  Epithelial Cell Adhesion Molecule Regulates Tumor Initiation and Tumorigenesis via Activating Reprogramming Factors and Epithelial-Mesenchymal Transition Gene Expression in Colon Cancer* , 2012, The Journal of Biological Chemistry.

[6]  Na Li,et al.  SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells , 2012, PloS one.

[7]  A. Pandiella,et al.  Sox2 expression in breast tumours and activation in breast cancer stem cells , 2012, Oncogene.

[8]  M. Mihm,et al.  SOX2 contributes to melanoma cell invasion , 2012, Laboratory Investigation.

[9]  H. Mellstedt,et al.  Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. , 2012, Cancer treatment reviews.

[10]  O. Gires,et al.  EpCAM and its potential role in tumor-initiating cells , 2012, Cell adhesion & migration.

[11]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[12]  I. Ellis,et al.  EpCAM expression is an indicator of recurrence in basal-like breast cancer , 2012, Breast Cancer Research and Treatment.

[13]  J. Neumann,et al.  SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer , 2011, BMC Cancer.

[14]  Y. Toiyama,et al.  Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. , 2011, Oncology reports.

[15]  O. Gires.  Lessons from common markers of tumor-initiating cells in solid cancers , 2011, Cellular and Molecular Life Sciences.

[16]  S. Lakhani,et al.  Breast cancer stem cells: treatment resistance and therapeutic opportunities. , 2011, Carcinogenesis.

[17]  P. Went,et al.  EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.

[18]  J. Vieweg,et al.  E-cadherin plasticity in prostate cancer stem cell invasion. , 2011, American journal of cancer research.

[19]  C. Lengerke,et al.  Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma , 2011, BMC Cancer.

[20]  L. Dirix,et al.  An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Ashley M. Cimino,et al.  Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases , 2010, Breast Cancer Research and Treatment.

[22]  Dirk Hasenclever,et al.  Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer , 2008, Clinical Cancer Research.

[23]  Jing Liang,et al.  The Molecular Mechanism Governing the Oncogenic Potential of SOX2 in Breast Cancer* , 2008, Journal of Biological Chemistry.

[24]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[25]  M. Harmsen,et al.  Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. , 2007, The American journal of pathology.

[26]  R W Blamey,et al.  Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. , 2007, European journal of cancer.

[27]  J. Reis-Filho,et al.  Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer , 2007, Modern Pathology.

[28]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[29]  Y. Hannun,et al.  EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy , 2004, Cancer Research.

[30]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[31]  Markus Münz,et al.  The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.

[32]  I. B. Briaire-de Bruijn,et al.  Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. , 2003, Experimental cell research.

[33]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[35]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .